



# Regulatory Submissions, Information, and Document Management Forum

Primer: February 4 | Forum: February 5-7

Bethesda North Marriott Hotel and Conference Center | North Bethesda, MD

## PROGRAM CHAIRS

### Brooke Casselberry, MSRA, RAC

Owner  
Cyan Life Sciences

### Michelle Charles, MPH

Director, Regulatory Affairs  
Gene Therapy Program and Orphan Disease Center  
University of Pennsylvania, Perelman School of Medicine

### Jamie Marie Toth

Director, TMF Operations  
Daiichi Sankyo, Inc.

### Ron D. Fitzmartin, DIA Fellow, PhD, MBA

Senior Advisor, Data Standards Program Office of Strategic Programs  
CDER, FDA

## PROGRAM COMMITTEE

### V. "Bala" Balasubramanian, PhD, MBA

President and CEO  
Cabeus, Inc.

### Cindy Chiu

Director, Regulatory Affairs Operations and Quality Management  
Merck & Co., Inc

### Jake Doran

Chief Technology Officer  
Genpact Pharamalink

### Betsy Fallen, RN

Consultant  
BAFallen Consulting, LLC

### Virginia Hussong

Data Standards Program Manager, OD, BSS  
CBER, FDA

### Mark Gray

Senior Project Manager, Bioinformatics Support Staff, BSS  
CBER, FDA

### Thomas Noto, MS

Senior Director, Regulatory Operations  
Lexicon Pharmaceuticals

### Daniel Orfe, MS

President and CEO  
Regulatory eSubmissions, LLC

### Sarah Powell, RAC, FRAPS

President  
Powell Regulatory Services

### Vikesh Srivastava

Associate Director, Business Informatics Division, HPFB  
Health Canada

### Michiel Stam

Regulatory Information Scientist  
eCTDconsultancy B.V., The Netherlands

### Stacy Tegan

Manager, Regulatory Technology Consulting  
Accenture Accelerated R&D Services

### Peter Terbeek, MBA

Senior Director, Publishing, and Submission  
Astellas

## Overview

This Forum has experienced growth year after year in attendees, vendors, and presenters from industry and health authority representation, and 2018 is expected to continue this growth. Four tracks and daily health authority plenary sessions provide a comprehensive view of content and regulatory information management and submissions.

## Highlights

- Four Tracks to choose from to tailor the meeting for you (See page 2 for more information on tracks)
- Two interactive "Ask the Regulator" sessions.
- Multiple general plenary sessions and four breakout tracks to tailor the forum to meet your needs
- Preconference short courses for even more learning
- Regulatory intelligence updates by health authority representatives from FDA, Health Canada, and other regions
- Dinner on the Town on Tuesday to get to network and engage with your peers over a meal

## Who Should Attend?

Professionals involved in:

- Regulatory Affairs and Operations
- Regulatory Information Management
- Global Submission/Project Management
- Medical, Technical, and Regulatory Writing
- Data Management
- Information Technology and Support
- Document and eRecords Management
- Essential Document Process and Business Systems
- Regulatory Standards Implementation
- Clinical Operations
- Quality Assurance and Compliance
- Contract Researchers and Service Support
- Emerging Pharmaceutical/Biotech/Device
- Vendor Relationship Management

### Stay Connected!

Connect to the Complimentary Forum Wi-Fi

Network: **Marriott\_Conference**

Password: **RSIDM18**



800 Enterprise Road  
Suite 200  
Horsham, PA 19044 USA

#RSIDM18 | DIAGlobal.org

As of January 29, 2018.

## Tracks

**Track 1: RIM Business Track** addresses processes for obtaining and managing regulatory information, organizational impact, and key issues shaping the global regulatory and business environments.

**Track 2: RIM Technology Track** focuses on standards related to submission of regulatory information, tools to effectively manage the information, implementation experiences and results, and implications for refinement.

**Track 3: Electronic Document Management (EDM) Track** examines the processes, systems, and best practices for content management across the product lifecycle, including alignment with the RIM system for optimal use of regulatory information.

**Track 4: Electronic Regulatory Submissions (ERS) Track** explores the submission process, regulatory requirements and new developments, best practices in regulatory submissions, and industry adoption techniques.

### Download the DIA Global Mobile App!

It is designed to enhance your meeting experience and provide valuable information in one place: agenda and speaker information, presentations, connect with attendees and exhibitors, participate in live session polling, and more!

**Search “DIA Global” in your app store.**

*Your initial password is ‘global’. If you have previously used this app, please use your existing password or reset your password.*



### Join Us Next Year!

February 11-13, 2019

Bethesda North Marriott Hotel and  
Conference Center

Registration Opens Monday, February 5.  
Lock in 2018 Rates before May 1!

[DIAglobal.org/RSIDM19](http://DIAglobal.org/RSIDM19)



# Schedule At-A-Glance

**Track 1:** RIM Business **Track 2:** RIM Technology **Track 3:** EDM **Track 4:** ERS

PRIMER   SUNDAY, FEBRUARY 4		ROOM
9:30-10:30AM	Primer Registration	Forest Glen Foyer (Lower Level)
10:00AM-5:00PM	<b>Regulatory Content and Submissions Primer:</b> Tracking Content from Conception to Interment	Forest Glen
DAY ONE   MONDAY, FEBRUARY 5		ROOM
7:30AM-5:00PM	Registration	Ballroom Foyer (Upper Level)
8:30AM-12:00PM	<b>Short Course 1:</b> Global Identification of Medicinal Products (IDMP): Applied Principles and Practical Benefits from Compliance and Beyond	Brookside AB (Lower Level)
8:30AM-12:00PM	<b>Short Course 2:</b> Essentials for Compiling/Publishing Compliant Electronic Submissions (eCTDs)	Forest Glen
12:30-1:00PM	<b>DIA Global Mobile App Tutorial</b>	Ballroom E-H
1:00-1:30PM	<b>Welcoming Remarks and Presentation of the Volunteer Award</b>	Ballroom E-H
1:30-2:00PM	<b>Session 1:</b> Keynote Address: Introduction to Blockchain: Distributed Ledger Technology for Regulation and Supply Chain Security	Ballroom E-H
2:00-2:30PM	Refreshment Break in the Exhibit Hall	Ballroom A-D
2:30-3:45PM	<b>Session 2:</b> FDA Opening Plenary Panel: PDUFA VI Informatics	Ballroom E-H
3:45-5:00PM	<b>Session 3:</b> Other Regions Update	Ballroom E-H
5:00-6:00PM	Networking Reception in the Exhibit Hall	Ballroom A-D
DAY TWO   TUESDAY, FEBRUARY 6		ROOM
7:30AM-4:00PM	Registration	Ballroom Foyer
7:30-8:30AM	Networking Breakfast in the Exhibit Hall	Ballroom A-D
8:30-9:45AM	<b>Session 4:</b> New FDA Draft Guidance on Part 11 in Clinical Investigations and Mobile Technologies in Clinical Investigations	Ballroom E-H
9:45-10:30AM	<b>Session 5:</b> FDA Ask the Regulators: Part 1	Ballroom E-H
10:30-11:00AM	Refreshment Break in the Exhibit Hall	Ballroom A-D

# Schedule At-A-Glance

**Track 1:** RIM Business **Track 2:** RIM Technology **Track 3:** EDM **Track 4:** ERS

DAY TWO   TUESDAY, FEBRUARY 6		ROOM
<b>11:00AM-12:15PM</b>	<b>Session 6:</b> Breakout Sessions <b>Track 1:</b> HeRO Forum Benchmarking: Global Regulatory Sourcing Strategies for Evolving Regulatory and Industry Solution <b>Track 2:</b> The Increasingly Critical Roles of RIM Systems and Their Expanding Number of Use Cases Beyond Regulatory Affairs <b>Track 3:</b> Strategies for Ensuring Part 11/Annex 11 Compliance of eTMFs at Research Sites <b>Track 4:</b> eCTD AdPromo Panel Discussion	Ballroom FGH White Oak (Lower Level) White Flint (Lower Level) Brookside (Lower Level)
<b>12:15-1:45PM</b>	Networking Luncheon in the Exhibit Hall	Ballroom A-D
<b>1:45-3:00PM</b>	<b>Session 7:</b> Breakout Sessions <b>Track 1:</b> Paradigm Shift in Data Management and How to Enrich Business Intelligence to Benefit the Industry <b>Track 2:</b> How to Compete in the Data-Driven Digital Transformation in the Pharmaceutical Industry? <b>Track 3:</b> Understanding ICH E6 R2 and the Impact to Clinical Trial Documentation and the Trial Master File <b>Track 4:</b> Keeping up with Trends in eCTD: Submitting in US Module 1 Specification	Ballroom FGH White Oak (Lower Level) White Flint (Lower Level) Brookside (Lower Level)
<b>3:00-3:30PM</b>	Refreshment Break in the Exhibit Hall	Ballroom A-D
<b>3:30-4:45PM</b>	<b>Session 8:</b> Breakout Sessions <b>Track 1:</b> Processes - Don't Make Them an Afterthought <b>Track 2:</b> Transforming Regulatory Information Management Through Innovation <b>Track 3:</b> Creating and Streamlining Regulatory Dossier Management <b>Track 4:</b> Using Submission Management to Enable Streamlined Regulatory Planning	Ballroom FGH White Oak (Lower Level) White Flint (Lower Level) Brookside (Lower Level)
<b>5:30PM</b>	Dinner on the Town	
DAY THREE   WEDNESDAY, FEBRUARY 7		ROOM
<b>7:30AM-2:00PM</b>	Registration	Ballroom Foyer
<b>7:30-8:30AM</b>	Networking Breakfast in the Exhibit Hall	Ballroom A-D
<b>8:30-9:45AM</b>	<b>Session 9:</b> Breakout Sessions <b>Track 1:</b> Critical Success Factors for Implementation of Regulatory Information Management Capabilities <b>Track 2:</b> Driving Innovation in Regulatory Technology within Life Sciences <b>Track 3:</b> How to Utilize Systems and Technology as Document Enablers <b>Track 4:</b> Regulatory Sourcing: Regulatory Sourcing - Who is Doing What and Some Real-World Industry Experiences	Ballroom FGH White Oak (Lower Level) White Flint (Lower Level) Brookside (Lower Level)
<b>9:45-10:15AM</b>	Refreshment Break in the Exhibit Hall	Ballroom A-D
<b>10:15-11:30AM</b>	<b>Session 10:</b> Breakout Sessions <b>Track 1:</b> RIM 2020: Connecting to Other Functional Processes <b>Track 2:</b> Artificial Intelligence (AI): The Next Frontier <b>Track 3:</b> Panel Discussion: Managing Partnerships <b>Track 4:</b> TransCelerate, FDA, and NIH: The Evolution of a Common Protocol Template	Ballroom FGH White Oak (Lower Level) White Flint (Lower Level) Brookside (Lower Level)
<b>11:30AM-1:00PM</b>	Networking Luncheon in the Exhibit Hall	Ballroom A-E
<b>1:00-1:45PM</b>	<b>Session 11:</b> FDA Ask the Regulators: Part II	Ballroom E-H
<b>1:45-2:00PM</b>	<b>Closing Remarks</b>	Ballroom E-H
<b>2:00PM</b>	<b>Forum Adjourns</b>	

## Learning objectives

At the conclusion of this conference, participants should be able to:

- Explain the regulatory electronic submission process from the completion of its upload to the Electronic System Gateway (ESG) through the time the submission is made available to the review team
- Discuss the agency target time frames for the 1) expected submission upload duration(s) and 2) timeframe between key milestones and notifications
- Describe the current required data standards for regulatory submissions and the status of ongoing data standards initiatives
- Describe organizational processes and governance to ensure integrity, quality, and security of regulatory information (data, documents, records)
- Estimate the scope and future of data standards, including IDMP, with respect to systems, processes, and master data
- Discuss ways data can be harmonized, integrated, and viewed to provide an end-to-end view of the regulatory information value chain
- Discuss organizational implications related to increasing electronic interactions with stakeholders and health authorities
- Explain ways to improve processes and communication of regulatory activities including communications, end-to-end processes, and integration of systems for document, submission, and records management
- Interpret global health authority regulations and guidances for systems and business processes
- Identify ways in which the integration of data, documents, and knowledge can be leveraged to develop insights and enable better business decisions
- Identify changes in submission-related regulations impacting RIM business processes

## Continuing Education



DIA has been accredited as an Authorized Provider by the International Association for Continuing Education and Training (IACET).

As an IACET Authorized Provider, DIA offers CEUs for its programs that qualify under the ANSI/IACET Standard. DIA is authorized by IACET to offer up to **2.1** CEUs for this program. Participants must attend the entire program in order to be able to receive an IACET statement of credit. No partial credit will be awarded.

**Primer:** 0.6 CEUs

**Short Course 1:** 0.3 CEUs

**Short Course 2:** 0.3 CEUs

**Forum:** 1.2 CEUs

If you would like to receive a statement of credit, you must attend the forum (primer or short course, if applicable), sign in at the registration desk **each day**, and complete the online credit request process through My Transcript. Participants will be able to download a statement of credit upon successful submission of the credit request. My Transcript will be available for credit requests on **Wednesday, February 21, 2018**.

To view DIA's Grievance Policy, visit [DIAglobal.org/Grievance](http://DIAglobal.org/Grievance)

### TO ACCESS MY TRANSCRIPT

- Visit [DIAglobal.org](http://DIAglobal.org), select "Sign in" and you will be prompted for your user ID and password
- Choose MENU, found in the upper left corner
- Under CONFERENCES select "Continuing Education"
- Select the blue "My Transcript" button followed by "Credit Request" to process your credit request for the course

### ACCESS PRESENTATIONS

- Visit [DIAglobal.org](http://DIAglobal.org)
- Select 'Sign in' at the top right
- Enter your User ID and Password
- Go to 'My Account'
- View 'My Presentation'

Please Note: DIA User ID and Password are needed to access presentations. If you have forgotten your DIA User ID and Password, or this is your first time logging into the DIA website, please use our Login Reminder. *\*Presentations will be available for six months post conference.*

# PRIMER COURSE | FEBRUARY 4

9:30-10:30AM

## Primer Registration

10:00AM-5:00PM

## Regulatory Content and Submissions Primer

Tracking Content from Conception to Interment

### Instructors

**Betsy Fallen, RN**

Consultant

BAFallen Consulting, LLC

**Dan Orfe, MS**

President and CEO

Regulatory eSubmissions, LLC

This activity is designed to meet the needs of individuals who are either new to biopharmaceutical-based document management, information management, and regulatory submission publishing for authorities, or already experienced in one area, looking to gain a broader understanding of the full spectrum of the regulatory submission, information, and document management arena. Understanding the various steps throughout the life of document components from their conception, publishing into a submission, delivery to regulatory agencies, and ultimate company archival, will yield “ah-ha” moments for the attendees of this offering from all functions along the life-span of content.

### Learning Objectives

At the conclusion of this short course, participants should be able to:

- Describe the benefits of understanding the complete life phases of regulatory content and the impact that decisions in one place along the life path will have at other stages of the process
- Identify key drivers within each of the life phases and potential pros and cons associated with solution choices
- Recognize the needs of the other organizations involved within the life span of the regulatory content and fairly assess their concerns in process and procedure decision-making
- Comprehend the newly released regulations, guidelines, and industry best practices and gain an awareness of their impact

# DAY ONE | MONDAY, FEBRUARY 5

7:30AM-5:00PM

## Registration

8:30AM-12:00PM

## Short Course 1

Global Identification of Medicinal Products (IDMP): Applied Principles and Practical Benefits from Compliance and Beyond

### Session Chair

**Vada Perkins, MSc, MS**

Founder and Managing

Principal

Identifica, LLC

### Instructors

**Michiel Stam**

Regulatory Information

Scientist

**Andrew Marr**

Managing Director

Marr Consultancy, Ltd

**Frits Stulp, MSc**

Managing Director

Iperion Life Sciences

Consultancy, The Netherlands

In December 2010, new pharmacovigilance legislation was adopted by the European Parliament and European Council to require the use of common standards, formats and terminologies in the EU for the identification and exchange of information on medicines. Specific reference is made to the ISO Identification of Medicinal Product (IDMP) standards that were finalized in 2017 and the corresponding technical specifications developed with international standards development organizations (i.e., ISO and HL7). IDMP is a significant undertaking, but it also presents opportunities in terms of how Regulators and Industry manage and share data, both internally and externally, to support global product lifecycle data management.

This Short Course is aimed at providing stakeholders with a foundational knowledge of IDMP to support practical implementation within their organizations. More specifically, the tutorial will address issues within the regulatory landscape and demonstrate applied strategies for the implementation of the ISO IDMP to support global medicinal product identification. Topics to be addressed include a background of the IDMP standards and legislation, and an overview of the overall structure, content, and technical requirements of IDMP. More importantly, this tutorial will present practical examples and offer a demonstration of applied IDMP concepts to directly address regulatory initiatives and requirements. This session is applicable to entry and intermediate level stakeholders.

### Learning Objectives

At the conclusion of this short course, participants should be able to:

- Recognize the main features of the IDMP standards and corresponding technical specifications
- Understand the content and message exchange requirements for the submission of medicinal product information by relevant stakeholders
- Demonstrate applied strategies for the implementation of ISO IDMP beyond compliance (true benefit across the value chain within an organization)
- Understand and apply IDMP concepts regulatory and other business needs

8:30AM-12:00PM

## Short Course 2

Essentials for Compiling/Publishing Compliant Electronic Submissions (eCTDs)

### Instructors

#### Jillian Carinci, MS

Associate Director, Regulatory Operations  
Accenture Regulatory

#### Dan Orfe, MS

President and CEO  
Regulatory eSubmissions, LLC

Whether you've submitted 100 initial filings, or are preparing for your first one, getting your team ready for that initial submission is always important. Dotting all the i's and crossing all the t's can lead to a successful submission and make you better prepared for the rapid responses during agency information requests. This short course will walk through the important regulatory and clinical guidance documents, connecting them specifically to submission needs. It will break down specific requirements by Module, including specific points on SPL creation and data packages, while noting best practices to avoid the dreaded RTF.

### Learning Objectives

At the conclusion of this short course, participants should be able to:

- Understand best practices for US eCTD Submissions
- Recognize how clinical data packages impact the regulatory world
- Implement best practices for managing an application's lifecycle

12:30-1:00PM

## DIA Global Mobile App Tutorial

1:00-1:30PM

## Welcoming Remarks and Presentation of the Volunteer Award

### Sudip Parikh, PhD

Senior Vice President and Managing Director, DIA Americas  
DIA

### RSIDM Track Chairs

1:30-2:00PM

## Session 1

Keynote Address: Introduction to Blockchain: Distributed Ledger Technology for Regulation and Supply Chain Security

### Keynote Speaker

#### Jim St. Clair

Founder  
Institute for Healthcare Financial Technology

First made popular by Bitcoin and other digital currencies, Blockchain represents a new distributed ledger system that is being applied across multiple industries. Blockchain is being considered in multiple use cases in healthcare product management, supply chain security, and regulatory information. This presentation will provide a high-level overview of Blockchain-distributed ledger technology and its uses and pilot efforts in healthcare products.

2:00-2:30PM

## Refreshment Break in the Exhibit Hall

2:30-3:45PM

## Session 2

FDA Opening Plenary Panel: PDUFA VI Informatics

### Session Chair

#### Ron Fitzmartin, DIA Fellow, MBA, PhD

Senior Advisor, Data Standards Program, Office of Strategic Programs  
CDER, FDA

This session will provide an overview of the FDA electronic submission systems and data standards that impact sponsors applications from time of submission at the ESG through the time the submission is made available to the review team. In addition, receive an update on the CBER-CDER Joint Data Standards Strategy and Action Plan, and the Public Meeting scheduled for March 2018.

### Electronic Submissions Gateway Update

#### La Misha Fields

IT Program Manager, Electronic Submissions Gateway, OIMT, OC  
FDA

### Data Standards Strategy and Action Plan Update

#### Virginia Hussong

Data Standards Program Manager, OD, BSS  
CBER, FDA

### Electronic Submissions Update

#### Ethan Chen, MSE, MBA

Director, Division of Data Management Services and Solutions, OBI, OSP  
CDER, FDA

## DAY ONE | MONDAY, FEBRUARY 5

3:45-5:00PM

### Session 3

Other Regions Update

#### Session Chair

**Michiel Stam**

Regulatory Operations Consultant  
eCTDconsultancy B.V., The Netherlands

Receive updates about developments in other regions including Canada, European Union, and Japan. Hear agency and industry representatives speak about electronic submissions, development of new data standards, local implementation plans, and Health Authority IT strategies.

#### Vikesh Srivastava

Associate Director, Business  
Informatics Division, HPFB  
Health Canada

#### Mickel Hedemand, MSc

Special Advisor, Medicines  
Licensing, Workflow  
Danish Medicines Agency,  
Denmark

#### Harv Martens

Technical Expert for  
JPMA on ICH M2 and M8  
Expert Working Groups

5:00-6:00PM

**Networking Reception in the Exhibit Hall**

## DAY TWO | TUESDAY, FEBRUARY 6

7:30AM-4:00PM

**Registration**

7:30-8:30AM

**Networking Breakfast in the Exhibit Hall**

8:30AM-12:00PM

### Session 4

New FDA Draft Guidance on Part 11 in Clinical Investigations and Mobile Technologies in Clinical Investigations

#### Session Chair

**Ron Fitzmartin, DIA Fellow, MBA, PhD**

Senior Advisor, Data Standards Program, Office of Strategic Programs  
CDER, FDA

During this session, you will review the new 2017 FDA Guidance on 21 CFR Part 11 in Clinical Investigations and the public comments, discuss next steps, and hear from the audience on the topics presented.

#### Part 11 Guidance

**Cheryl Grandinetti, PharmD**

Health Scientist, Policy Analyst  
FDA

#### Regulatory Considerations in the Use of Mobile Technology in Clinical Investigations

**Leonard Sacks, MD**

Associate Director for Clinical Methodology, Office of Medical  
Policy  
CDER, FDA

9:45-10:30AM

### Session 5

FDA Ask the Regulators: Part 1

#### Session Chair

**Virginia Hussong**

Data Standards Program Manager, OD, BSS  
CDER, FDA

#### Speakers

**Ethan Chen, MSE, MBA**

Acting Director, Division of Data Management Services and  
Solutions, OS  
CDER, FDA

**Ron Fitzmartin, DIA Fellow, MBA, PhD**

Senior Advisor, Data Standards Program, Office of Strategic  
Programs  
CDER, FDA

**La Misha Fields**

IT Program Manager, Electronic Submissions Gateway, OIMT,  
OC  
FDA

**Cheryl A. Grandinetti, PharmD**

Health Scientist, Policy Analyst  
FDA

**Mark Gray**

Senior Project Manager, BSS  
CDER, FDA

**Jean M. Mulinde, MD**

Senior Policy Advisor, Office of Scientific Investigations, OC  
CDER, FDA

**Leonard Sacks, MD**

Associate Director for Clinical Methodology, Office of Medical  
Policy  
CDER, FDA

10:30-11:00AM

**Refreshment Break in the Exhibit Hall**





# DAY TWO | TUESDAY, FEBRUARY 6

11:00AM-12:15PM

## Session 6

Breakout Sessions

TRACK 1	TRACK 2	TRACK 3	TRACK 4
<p><b>HeRO Forum Benchmarking: Global Regulatory Sourcing Strategies for Evolving Regulatory and Industry Solution</b></p>	<p><b>The Increasingly Critical Roles of RIM Systems and Their Expanding Number of Use Cases Beyond Regulatory Affairs</b></p>	<p><b>Strategies for Ensuring Part 11/Annex 11 Compliance of eTMFs at Research Sites</b></p>	<p><b>eCTD AdPromo Panel Discussion</b></p>
<p><b>Session Chair</b>  <b>Jake Doran</b>                      Chief Technology Officer                      Genpact Pharamlink</p> <p>In this session, Mike Keech (Vice President, Head of US Advisory Services at Kinapse) will coordinate the presentations from the Heads of Regulatory Operations at three pharmaceutical companies. These leaders will share their organizational approaches to building a regulatory function in 2018. They will share their challenges, successes, and thoughts of where Regulatory is headed in the future and how you can prepare for the upcoming changes within your own organization.</p> <p><b>Michael Keech</b>                      Vice President, Advisory                      Kinapse</p> <p><b>Karen Towns</b>                      Vice President, Publishing, and Product License Support                      Pfizer, Inc</p> <p><b>Eckart Schwarz</b>                      Senior Vice President, Global Quality and Compliance                      GlaxoSmithKline</p> <p><b>David Berglund</b>                      Global Head of Regulatory Operations                      AstraZeneca</p>	<p><b>Session Chair</b>  <b>Michiel Stam</b>                      Regulatory Information Scientist                      eCTDconsultancy B.V., The Netherlands</p> <p>RIM systems play an increasingly critical role in our organizations and their scope and use cases extend further beyond the Regulatory Affairs department. This session will focus on strategies and best practices for redefining and implementing RIM systems within today's organization to successfully support a wide range of applications.</p> <p><b>Global Use Cases and Practical Challenges of Managing Regulatory Information from a Single Source of Truth</b>  <b>Michiel Stam</b>                      Regulatory Information Scientist                      eCTDconsultancy B.V., The Netherlands</p> <p><b>Foundational RIM Strategy for a Small- to Medium-Size Enterprise</b>  <b>Vahe Ghahraman, PhD</b>                      Senior Director                      Alexion Pharma</p> <p><b>Manage Change...Don't Let Change Manage You</b>  <b>Sue Metz</b>                      Vice President, Technical                      PAREXEL International</p>	<p><b>Session Chair</b>  <b>James Riddle, MCSE, CIP, CPIA</b>                      Vice President of Client Services                      Kinetiq, a Division of Quorum IRB</p> <p>Don't be caught off guard with a preventable compliance finding. Building a risk-based Part 11/Annex 11 compliance program at research sites is easier than most think. FDA has made it clear in recent draft guidance that electronic regulatory master files and other 'e' systems are subject to Part 11 regulations. All parties need to understand the requirements and develop strategies for compliance.</p> <p><b>James Riddle, MCSE, CIP, CPIA</b>                      Vice President of Client Services                      Kinetiq, a Division of Quorum IRB</p> <p><b>Darren Lacey</b>                      Chief Information Security Officer                      Johns Hopkins University</p> <p><b>Lawrence Rich</b>                      Partner                      Gxp Authority</p>	<p><b>Session Chair</b>  <b>Thomas Noto</b>                      Senior Director, Regulatory Operations                      Lexicon Pharmaceuticals</p> <p>Although the eCTD AdPromo Guidance from the FDA has been out for more than two years, the majority of companies haven't switched this process to eCTD. Commonly heard excuses are that it is complicated, expensive, and just too hard to change a process that entails hundreds of submissions a year per marketed product. This session will be an informative and fun panel discussion with seasoned experts who have made the switch to submitting AdPromo materials in eCTD format within their own companies, and lived to tell about it.</p> <p><b>Josephine Secnik, MS, MBA</b>                      Director, Ad/Promo Regulatory Affairs                      Eli Lilly and Company</p> <p><b>Thomas Noto</b>                      Senior Director, Regulatory Operations                      Lexicon Pharmaceuticals</p> <p><b>Thomas Christensen, RAC</b>                      Senior Regulatory Affairs Manager                      SynteractHCR</p>

12:15-1:45PM

**Networking Luncheon in the Exhibit Hall**



# DAY TWO | TUESDAY, FEBRUARY 6

1:45-3:00PM

## Session 7

Breakout Sessions

<b>TRACK 1</b> Paradigm Shift in Data Management and How to Enrich Business Intelligence to Benefit the Industry	<b>TRACK 2</b> How to Compete in the Data-Driven Digital Transformation in the Pharmaceutical Industry?	<b>TRACK 3</b> Understanding ICH E6 R2 and the Impact to Clinical Trial Documentation and the Trial Master File	<b>TRACK 4</b> Keeping up with Trends in eCTD: Submitting in US Module 1 Specification
<p><b>Session Chair</b>  <b>Brooke Casselberry, MSRA, RAC</b>                      Owner                      Cyan Life Sciences</p> <p>This session covers case studies from three top biopharmaceutical companies and how they are changing the way they use data in their organizations. You will learn how organizations are using data and standards in more expansive ways. You will hear directly from peers on the steps taken to change the current thinking in their organizations on data, RIM, IDMP, and overall standards.</p> <p><b>Case Study – Implementing a Paradigm Shift in RIM Data Management: From Administrative Afterthought to Strategic Asset</b>  <b>Kelly Hnat</b>                      Principal                      K2 Consulting</p> <p><b>Case Study – Improvement of Collaboration Across Industries</b>  <b>Andrea Herrmann, PhD</b>                      Director, Strategy Implementation Leader                      Merck KGaA, Germany</p> <p><b>Case Study – Enhanced Planning for Due Diligence and M&amp;A Using the ISO IDMP Data Model</b>  <b>John Stanek</b>                      Senior Associate, Global Regulatory Affairs                      Johnson &amp; Johnson Group of Consumer Companies</p>	<p><b>Session Chair</b>  <b>Jake Doran</b>                      Chief Technology Officer                      Genpact Pharmedlink</p> <p>The introduction of the digital transformation across life sciences is now in full swing. Being successful in the digital age requires a different approach than what has been done in the past. Pharmaceutical companies have often felt that their products were their biggest asset, however, it is becoming abundantly clear the most important asset of any company is the data. In this session, we will look at various elements of the technology ecosystem being forged across the industry and what is required in order to manage and succeed in this new world.</p> <p><b>How to Compete in the Data Driven Digital Transformation in the Pharmaceutical Industry?</b>  <b>Morten Lindaa, MSc</b>                      Consulting Director, Life Sciences                      NNIT, Denmark</p> <p><b>Achieving Digital Transformation in Regulatory</b>  <b>Cary Smithson, MBA</b>                      Principal Consultant                      OpenText Corporation</p> <p><b>Case Studies in Digital Transformation Across Life Sciences</b>  <b>Jake Doran</b>                      Chief Technology Officer                      Genpact Pharmedlink</p>	<p><b>Session Chair</b>  <b>Joanne Malia, MSc</b>                      Associate Director, Clinical Documentation Management                      Regeneron Pharmaceuticals</p> <p>ICH E6 R2 was released in November 2016 and has outlined new expectations for all stakeholders of clinical trials. Additionally, the EMA released its draft guidance on the Trial Master File (TMF). This session will discuss the resulting expectations impacting clinical trial documentation and the TMF. The impact and response from different stakeholders such as vendors, sponsors, and regulators will be presented and discussed.</p> <p><b>Fran Ross</b>                      Associate Director, Clinical and Regulatory Optimization                      Paragon Solutions</p> <p><b>Joanne Malia, MSc</b>                      Associate Director, Clinical Documentation Management                      Regeneron Pharmaceuticals</p> <p><b>Ann McCabe</b>                      Director, Process Excellence and Risk Management                      Daiichi Sankyo, Inc.</p>	<p><b>Session Chair</b>  <b>Peter Terbeek, MBA</b>                      Senior Director, Publishing, and Submission                      Astellas</p> <p>This session will explore the good, the bad, and the ugly of transitioning to the new US Module 1 Specification. We will examine considerations and obstacles for converting and hear from a vendor on how to support a mixed portfolio. We will cover software and validation considerations, training to understand the regulatory changes, and US M1 metadata and new document fields. This session will encourage your participation by asking questions and polling your experiences.</p> <p><b>Transitioning to ECTD, a Small Company Perspective</b>  <b>Greg May</b>                      Associate Director, Regulatory Affairs                      Nabriva Therapeutics</p> <p><b>Managing a Global Portfolio, a Large Company Perspective</b>  <b>Jennifer Moore</b>                      Manager, GRAAS Ops                      Publishing                      Amgen, Inc.</p> <p><b>Supporting Multiple Specifications Simultaneously, a Vendor Perspective</b>  <b>Sandra Krogulski, MA</b>                      Regulatory Operations                      Submission Manager                      Accenture Regulatory</p>
<p>3:00-3:30PM <b>Refreshment Break in the Exhibit Hall</b></p>			



# DAY TWO | TUESDAY, FEBRUARY 6

3:30-4:45PM

## Session 8

Breakout Sessions

<b>TRACK 1</b> <b>Processes - Don't Make Them an Afterthought</b>	<b>TRACK 2</b> <b>Transforming Regulatory Information Management Through Innovation</b>	<b>TRACK 3</b> <b>Creating and Streamlining Regulatory Dossier Management</b>	<b>TRACK 4</b> <b>Using Submission Management to Enable Streamlined Regulatory Planning</b>
<p><b>Session Chair</b>  <b>Sarah Powell, RAC, FRAPS</b>                      President                      Powel Regulatory Services</p> <p>Organizations often ignore one of the most critical success factors when implementing new technology – process definition. Learn how other organizations have approached process definition as an aid to successful implementations and change management.</p> <p><b>Successful Process Definition Methodology</b>  <b>Sarah Powell, RAC, FRAPS</b>                      President                      Powell Regulatory Services</p> <p><b>Importance of Well-Defined and Documented Processes to Your RIM Program</b>  <b>Elizabeth Turek</b>                      Head, Knowledge Management                      Johnson &amp; Johnson</p>	<p><b>Session Chair</b>  <b>V. “Bala” Balasubramanian, PhD., MBA</b>                      President and CEO                      Cabeus, Inc.</p> <p>How can data-intensive regulatory business processes be supported by rich information management applications where expectations of ubiquity and better user experience are of utmost importance? What can enterprise implementations of systems learn from consumer applications such as Amazon? What is the industry doing about taking an end-to-end view of regulatory information management (RIM)? This session will have a reputed panel of experts sharing their views on how the industry must innovate and transform to the next generation of capabilities.</p> <p><b>Information and Connection</b>  <b>Matt Neal, MA</b>                      Senior Director, Product Management                      PARAXEL International</p> <p><b>Eliminating White Space in Managing Marketing Products</b>  <b>Peter Lassoﬀ, PharmD</b>                      Vice President and Head, Global Regulatory Affairs                      IQVIA</p> <p><b>DIA’s RIM Working Group: Its Mission, Vision, and Value to Industry</b>  <b>Jim Nichols</b>                      Executive Director, Life Sciences                      Cunesoft, Inc.</p>	<p><b>Session Chair</b>  <b>Cindy Chiu</b>                      Director, Regulatory Affairs Operations, and Quality Management                      Merck &amp; Co., Inc.</p> <p>This session will provide tried-and-tested methods for creating and streamlining regulatory dossier management. This includes a deep dive into the implementation of a cloud-based EDMS at a small biotech and how it established a ‘one stop shop’ for regulatory content reporting and tracking. Also, learn leading practices for expanding regulatory initiatives across the globe by taking a single-dossier approach to product registrations.</p> <p><b>Designing and Implementing an Integrated Regulatory Experience</b>  <b>Richard Fredericks, MBA</b>                      Associate Director, Regulatory Systems and Information Management                      Tesaro</p> <p><b>Take a Global Approach to Regulatory Dossier Management</b>  <b>Alex Butler, MBA</b>                      Product Marketing Manager                      MasterControl</p> <p><b>Lillian Erickson, MCP</b>                      QA/RA Director, Gas Sending, Analysis, and Delivery                      Maxtec, LLC</p>	<p><b>Session Chair</b>  <b>Michelle Charles, MPH</b>                      Director, Regulatory Affairs Gene Therapy Program and Orphan Disease Center                      University of Pennsylvania, Perelman School of Medicine</p> <p>This session will focus on how you can work business efficiency and project management into all aspects of regulatory submissions. We will begin with a presentation focused on the implementation of a global submission planning tool to enable portfolio management, then move to a presentation optimizing submission resources, and end with how to efficiently manage a submission lifecycle.</p> <p><b>Enabling Global Regulatory Submission Project and Portfolio Management Via a Unified Submission Planning Toolset</b>  <b>Laura Shelley, RPh, PMP</b>                      GRACS – Regulatory Portfolio and Submission Management                      Merck &amp; Co., Inc.</p> <p><b>Submission Lifecycle Management</b>  <b>Laurie Henricks</b>                      Director, Regulatory Submissions Operations                      Cardinal Health Regulatory Sciences</p> <p><b>Utilizing Submissions Management to Free up Resources in Regulatory Affairs</b>  <b>Stephanie Hughes</b>                      Regulatory Submissions Management Associate                      Teva Pharmaceuticals Inc.</p>

5:30-7:30PM

## Dinner on the Town

Traveling on your own or looking to connect with fellow attendees? Visit the DIA Registration Desk to link up for dinner! Sign up sheets will be provided for various local restaurants. Cost of dinner is the responsibility of the individual attendee.



# DAY THREE | WEDNESDAY, FEBRUARY 7

7:30AM-2:00PM	<b>Registration</b>			
7:30-8:30AM	<b>Networking Breakfast in the Exhibit Hall</b>			
8:30-9:45AM	<b>Session 9</b> Breakout Sessions			
	<p style="text-align: center;"><b>TRACK 1</b></p> <p style="text-align: center;"><b>Critical Success Factors for Implementation of Regulatory Information Management Capabilities</b></p>	<p style="text-align: center;"><b>TRACK 2</b></p> <p style="text-align: center;"><b>Driving Innovation in Regulatory Technology within Life Sciences</b></p>	<p style="text-align: center;"><b>TRACK 3</b></p> <p style="text-align: center;"><b>How to Utilize Systems and Technology as Document Enablers</b></p>	<p style="text-align: center;"><b>TRACK 4</b></p> <p style="text-align: center;"><b>Regulatory Sourcing: Regulatory Sourcing - Who is Doing What and Some Real-World Industry Experiences</b></p>
9:45-10:15AM	<b>Refreshment Break in the Exhibit Hall</b>			

**Session Chair**  
**V. "Bala" Balasubramanian, PhD, MBA**  
President and CEO  
Cabeus, Inc.

As organizations embark on transformational changes to their RIM systems, they must begin with a thorough understanding of business processes and requirements and focus on critical success factors such as business process transformation, organizational design, and change management, in addition to innovative technologies. This session will have a reputed panel of experts sharing their views on how organizations must focus on critical success factors to transform the RIM landscape.

**Actionable Regulatory Intelligence as a Service**  
**V. "Bala" Balasubramanian, PhD, MBA**  
President and CEO  
Cabeus, Inc.

**Did the Emperor Forget His Clothes? Why Any Successful Technology or System Implementation Begins with Defining His Outfit**  
**Kristen Sauter, MBA**  
Director, R&D Consulting, and Regulatory Practice Lead  
Paragon Solutions

**The Use of SPOR/IDMP and the Impact on Regulatory Affairs and RIM Solutions in the EU**  
**Remco Munnik**  
Regulatory Information Director  
Asphalion S.L., Spain

**Session Chair**  
**Vikesh Srivastava**  
Associate Director, Business Informatics Division, HPFB  
Health Canada

This session will cover digital innovation in regulatory information management technology, its impacts on the Life Sciences industry, and a perspective for the future. In addition, we will discuss how regulatory interactions are expected to change, particularly considering recent advances in analytics, real world evidence, machine learning, and mobile health, as well as the challenges this brings for both the industry and regulatory authorities. The discussion will speak to industry case studies.

**Lifecycle Data Management: Practical Application of Data Standards, Innovation, and Technology for Global Regulatory Convergence**  
**Vada Perkins, MSc, MS**  
Founder and Managing Principal  
Identifica, LLC

**Navigating the Regulatory Landscape of Innovation and Technology**  
**Representative Invited**  
Deloitte LLP, United Kingdom

**Q/A-Industry Perspective on Adoption of Data Standards and Technology**  
**John Kiser, MSc**  
Principal  
Kiser Regulatory Consulting Services

**Session Chair**  
**Jamie Marie Toth**  
Director, TMF Operations  
Daiichi Sankyo, Inc.

This session will focus on utilizing technology within the EDMS space and the importance of applying business process, utilizing system vendors as partners, and having technology be a differentiator and improve interoperability.

**Successful Business Process Driven EMDS Implementation in Less Than Nine Months**  
**Cheryl Resslerand**  
Executive Director, Regulatory Operations  
Daiichi Sankyo, Inc.

**Dalia El-Sherif, DrSc, PhD**  
Partner  
Pyxa Solutions

**Structured Content Management: Auto-Population and Auto-Generation of Documents at Roche**  
**Hans van Bruggen, MSc**  
Regulatory Affairs Scientist  
eCTDconsultancy B.V., The Netherlands

**eTMF Interoperability: The Move Towards Content Portability**  
**Christina Mantzioros, MS**  
Clinical Solutions Specialist  
Montrium, Inc., Canada

**Session Chair**  
**Daniel Orfe, MS**  
President and CEO  
Regulatory eSubmissions, LLC

Regulatory submission outsourcing has been a major component in submission publishing for the past decade. Changes in technology and real-world industry experiences have contributed to a reexamination of outsourcing. This session will provide benchmarking and trending information regarding the use of outsourcing looking back over the past 10 years of industry tracking. An exploration will be provided on outsourcing practices over time, activities being brought back in house, and which regions are becoming more active in leveraging outsourcing. Two industry organizations will provide insights into their own experiences with outsourcing touching on the pros, cons, beneficial strategies, and pitfalls to avoid.

**Regulatory Sourcing - Who is Doing What?**  
**Steve Gens, MS**  
Managing Partner  
Gens and Associates, Inc.

**Sourcing Experiences and Insights - Pros, Cons, Beneficial Strategies, and Pitfalls**  
**Heather Sinsel**  
Manager, Regulatory Operation and Submissions  
Inovio Pharmaceuticals, Inc.

**We Have How Many Submissions?!? Sourcing at a High-Volume Organization**  
**Kevin Tompkins, MS, MBA**  
Director North America, Regulatory Submissions Management  
Teva Pharmaceuticals

# DAY THREE | WEDNESDAY, FEBRUARY 7

10:15-11:30AM

## Session 10

Breakout Sessions

TRACK 1	TRACK 2	TRACK 3	TRACK 4
<p><b>RIM 2020: Connecting to Other Functional Processes</b></p> <p><b>Session Chair</b>  <b>Sarah Powell, RAC, FRAPS</b>                      President                      Powell Regulatory Services</p> <p>This session will provide information on how other companies are thinking and connecting their RIM capabilities with other functional systems and processes. It will be a combination of industry presenters and the latest benchmarking research.</p> <p><b>RIM 2020: Connecting to Other Functional Processes</b>  <b>Steve Gens, MS</b>                      Managing Partner                      Gens and Associates, Inc.</p> <p><b>RIM: Delivering Value for Regulatory and the Enterprise</b>  <b>James Hanly, MBA</b>                      Head IT Business Partner, Global Regulatory, Safety Biometrics                      Bristol Myers Squibb</p>	<p><b>Artificial Intelligence (AI): The Next Frontier</b></p> <p><b>Session Chair</b>  <b>Brooke Casselberry, MSRA, RAC</b>                      Owner                      Cyan Life Sciences</p> <p>This session will provide an overview of Artificial Intelligence (AI) technologies such as robotic process automation (RPA), natural language processing (NLP), and machine learning, and offer insight into how these AI technologies are developed and applied to regulatory affairs. Speakers will share their recent experience with implementing AI projects, their decision processes, and lessons learned along the way.</p> <p><b>Smart Regulatory Affairs: From Document Creation to Supported Decision-Making</b>  <b>Adair Turner, MSc, RAC</b>                      Principal Consultant, Director Regulatory Operations                      PharmaLex GmbH</p> <p><b>Using Artificial Intelligence to Augment Regulatory Affairs Knowledge</b>  <b>Nicholas Drago, RAC</b>                      Assistant Director, Regulatory Policy, and Intelligence                      Bayer Pharmaceuticals</p> <p><b>A Journey from Automation to AI within Regulatory Operations</b>  <b>Cesar Vincas</b>                      Director, Head of US and Canada Submissions Management, Regulatory Operations                      Pfizer, Inc</p>	<p><b>Panel Discussion: Managing Partnerships</b></p> <p><b>Session Chair</b>  <b>Sholeh Eghaivand</b>                      President and CEO                      LMK Clinical Research Consulting</p> <p>This panel-style presentation will detail examples of how partnerships with CROs and vendors can be properly managed for clinical trial success. The panel will discuss how metrics can help support measurable actions and manage CRO/vendor partnerships.</p> <p><b>Sharon Scricca</b>                      Associate Director, Submission Services, GDM                      Bristol-Myers Squibb</p>	<p><b>TransCelerate, FDA, and NIH: The Evolution of a Common Protocol Template</b></p> <p><b>Session Chair</b>  <b>Stacey Tegan</b>                      Manager, Regulatory Technology Consulting                      Accenture Accelerated R&amp;D Services</p> <p>The TransCelerate Common Protocol Template and the NIH-FDA Protocol Template are tools available to facilitate authoring of streamlined, harmonized protocols. Learn about the collaboration between these organizations. Hear from an FDA reviewer on the protocol review process and why this harmonization is critical to regulators. This session will include a demonstration of the electronic protocol tool which enables content reuse.</p> <p><b>An FDA Reviewer's Perspective on the Common Protocol Template</b>  <b>Eileen Navarro Almarino, MD, MS, FACP</b>                      Lead Medical Officer, OCS, OTS                      CDER, FDA</p> <p><b>Collaboration between NIH, FDA, and TransCelerate to Create Harmonized Protocol Templates Representative Invited</b></p> <p><b>TransCelerate's Technology Enabled Common Protocol Template</b>  <b>Mitzi Allred, PhD</b>                      Director, Clinical Trial Operations                      Merck &amp; Co., Inc.</p>

11:30AM-1:00PM

## Networking Luncheon in the Exhibit Hall

1:00-1:45PM

## Session 11

FDA: Ask the Regulators: Part II

### Session Chair

**Mark Gray**  
 Senior Project Manager, BSS  
 CBER, FDA

### Speakers

**Ethan Chen, MSE, MBA**  
 Director, Division of Data Management Services and Solutions, OS  
 CDER, FDA

**La Misha Fields**  
 IT Program Manager, Electronic Submissions Gateway, OIMT, OC  
 FDA

**Ron Fitzmartin, DIA Fellow, MBA, PhD**  
 Senior Advisor, Data Standards Program, Office of Strategic Programs  
 CDER, FDA

**Valerie Gooding**  
 Regulatory Information Specialist, OBI, OSP  
 CDER, FDA

**Jonathan Resnick**  
 Project Management Officer, OBI, OSP  
 CDER, FDA

1:45-2:00PM

## Closing Remarks

RSIDM Track Chairs

2:00PM

## Forum Adjourns





# DIA 2018

GLOBAL ANNUAL MEETING  
BOSTON | JUNE 24-28



[DIAGlobal.org/DIA2018](http://DIAGlobal.org/DIA2018)